Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP2 | P42575 | 1/20 | 0.67 |
| ▸ | NAAA | Q02083 | 1/20 | 0.62 |
| ▸ | EPHX1 | P07099 | 8/20 | 0.61 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.57 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.57 |
| ▸ | FAAH | O00519 | 4/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6161577 | 1.00 | CASP2 (0.67) | CASP2NAAAEPHX1ZDHHC20ZDHHC2 | |
| SCHEMBL6162878 | 1.00 | CASP2 (0.67) | CASP2NAAAEPHX1ZDHHC20ZDHHC2 | |
| SCHEMBL6164920 | 1.00 | CASP2 (0.67) | CASP2NAAAEPHX1ZDHHC20ZDHHC2 | |
| SCHEMBL6164193 | 1.00 | CASP2 (0.67) | CASP2NAAAEPHX1ZDHHC20ZDHHC2 | |
| SCHEMBL6163638 | 0.98 | CASP2 (0.63) | CASP2NAAAEPHX1ZDHHC20ZDHHC2 | |
| SCHEMBL351990 | 0.91 | — | — | |
| SCHEMBL14370358 | 0.84 | CASP2 (0.75) | CASP2NAAAEPHX1ZDHHC20ZDHHC2 | |
| SCHEMBL14890990 | 0.84 | CASP2 (0.75) | CASP2NAAAEPHX1ZDHHC20ZDHHC2 | |
| SCHEMBL9548566 | 0.84 | CASP2 (0.75) | CASP2NAAAEPHX1ZDHHC20ZDHHC2 | |
| SCHEMBL11923736 | 0.84 | CASP2 (0.75) | CASP2NAAAEPHX1ZDHHC20ZDHHC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2570418-A2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-03-20 | — | — | EP | disclosed |
| EP-1555267-B1 | 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES | OTSUKA PHARMA CO LTD (JP) | 2013-01-16 | — | — | EP | disclosed |
| US-7262212-B2 | 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2007-08-28 | — | — | US | disclosed |
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2006-05-04 | — | — | US | disclosed |
| EP-1555267-A1 | 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2005-07-20 | — | — | EP | disclosed |
| EP-1055712-B1 | Aqueous ink for ink jet recording | MITSUI CHEMICALS INC (JP) | 2005-02-16 | — | — | EP | disclosed |
| EP-1055712-A2 | Aqueous ink for ink jet recording | Mitsui Chemicals, Inc. (JP) | 2000-11-29 | — | — | EP | disclosed |
| US-6147051-A | ANTIISCHEMIC AGENT | TAKEDA CHEMICAL INDUSTRIES LTD. (JP) | 2000-11-14 | — | — | US | disclosed |
| EP-0777658-B1 | SUBSTITUTED TRIAZOLINONES AS PLANT PROTECTIVE AGENTS | BASF AG (DE) | 1999-12-15 | — | — | EP | disclosed |
| US-5885934-A | HERBICIDES OR FOR THE DESICCATION/DEFOLIATION OF PLANTS | BASF AKTIENGESELLSCHAFT (DE) | 1999-03-23 | — | — | US | disclosed |
| EP-0499266-B1 | Endothelin antagonist | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 1996-07-10 | — | — | EP | disclosed |
| WO-1996005179-A1 | SUBSTITUTED TRIAZOLINONES AS PLANT PROTECTIVE AGENTS | BASF AKTIENGESELLSCHAFT (DE) | 1996-02-22 | — | — | WO | disclosed |
| EP-0626174-A2 | Methods and compositions for the prophylactic and/or therapeutic treatment of organ hypofunction | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-11-30 | — | — | EP | disclosed |
| US-5352659-A | Polypeptide; hypotensive agents | TAKEDA CHEMICAL INDUSTRIES (JP) | 1994-10-04 | — | — | US | disclosed |
| US-5306808-A | Endothelin derivatives | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1994-04-26 | — | — | US | disclosed |
| EP-0547317-A1 | Endothelin antagonists | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1993-06-23 | — | — | EP | disclosed |
| EP-0499266-A1 | Endothelin antagonist | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1992-08-19 | — | — | EP | disclosed |
| EP-0470256-A1 | PEPTIDE DERIVATIVES AND PRODUCTION THEREOF | Takeda Chemical Industries, Ltd. (JP) | 1992-02-12 | — | — | EP | disclosed |
| WO-1991013089-A1 | PEPTIDE DERIVATIVES AND PRODUCTION THEREOF | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1991-09-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094767-A1 | 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles | NR2C2, NR4A3, NR4A2 | CASP2 2099/4885NAAA 2414/4885EPHX1 4071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.